The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Many studies have shown that genetic polymorphisms of the CYP2C9 gene contribute to some of the variability (around 20%) in warfarin dose requirements and therapeutic response to the drug. It is also clear that this effect must be elicited through difference...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Dickinson, Gemma L, Lennard, Martin S, Tucker, Geoffrey T, Rostami-Hodjegan, Amin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Science Inc 2007
Pynciau:
Pharmacokinetics & Pharmacodynamics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000610/
https://ncbi.nlm.nih.gov/pubmed/17298479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02850.x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg